GuidoLancmanMD

Physician

Dr. Lancman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Icahn School of Medicine at Mount Sinai (Bronx)Residency, Internal Medicine, 2015 - 2018
Icahn School of Medicine at Mount SinaiClass of 2015

PubMed

22 citations
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies.
Guido Lancman, Kian Parsa, Krzysztof Kotlarz, Lisa Avery, Alaina Lurie
Blood Cancer Discovery. 2023-11-01
17 citations
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.
Tarek H Mouhieddine, Oliver Van Oekelen, David T Melnekoff, Jeanne Li, Yogita Ghodke-Puranik
Blood Advances. 2023-03-28
2 citations
Trial designs and endpoints for immune therapies in multiple myeloma.
Guido Lancman, Erin Moshier, Hearn Jay Cho, Samir Parekh, Shambavi Richard
American Journal of Hematology. 2023-03-01

Abstracts/Posters

Impact of Primary Antibacterial Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients
Guido Lancman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Intravenous Immunoglobulin May Prevent Severe Infections Associated with Anti-BCMA Therapy for Multiple MyelomaSeptember 30th, 2023
IV Immunoglobulin May Cut Infection Risk of Anti-BCMA Agents for MyelomaOctober 1st, 2023
IVIg Reduces Infection Rate in Multiple Myeloma Patients Receiving Anti-BCMA TherapyOctober 7th, 2023